Collagen-targeted PET Imaging for Early Interstitial Lung Disease
Massachusetts General Hospital
Summary
The goal of this study is to investigate the ability of \[68Ga\]CBP8 to detect collagen deposition in early interstitial lung disease.
Description
\[68Ga\]CBP8, is a PET imaging probe which selectively binds collagen type I. Collagen deposition is a pivotal event in the development of pulmonary fibrosis. \[68Ga\]CBP8 binds collagen with high affinity and has excellent pharmacological and pharmacokinetic profiles. \[68Ga\]CBP8 was shown in a mouse model to be effective for detecting lung fibrosis and response to treatment. In addition, \[68Ga\]CBP8 can detect increased collagen in the lungs of patients with idiopathic pulmonary fibrosis. The goals of this study are: 1. To determine whether collagen deposition as assessed by \[68Ga\]CBP8…
Eligibility
- Age range
- 40+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: Group 1: First degree relatives of a family member with pulmonary fibrosis (n=8) * Age greater than 40 years * Have the ability to give written informed consent * First degree relative of a family member with pulmonary fibrosis * No known history of interstitial lung disease * No tobacco use within the prior 6 months. Group 2: Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) (n=22) * Age greater than 40 years * Have the ability to give written informed consent * ILAs or early ILD (defined by presence of reticular markings and / or…
Interventions
- Drug[68Ga]CBP8
An injection of up to 350 MBq of \[68Ga\]CBP8 will be administered intravenously followed by PET-MRI.
- DrugDotarem
Dotarem will be administered during MRI portion of study.
Location
- Massachusetts General HospitalBoston, Massachusetts